Scott Dehm (@scottdehm) header
Scott Dehm (@scottdehm) profile picture

Professor @UMNcancer studying steroid hormones, androgen receptors, and #ProstateCancer genomes. Apogee Enterprises Chair in Cancer Research . Views=mine.

Minneapolis, MN
Joined May 2011
Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)Photo by Scott Dehm (@scottdehm)
Drs. @scottdehm, Qi Cao, and Rendong Yang led this @NatureComms study investigating the interplay between super-enhancers and lncRNAs through analysis of lncRNA expression in a cohort of metastatic castration-resistant #ProstateCancer patients. 💡 go.nature.com/4lAqoPi
2
4
256
Today in @CCR_AACR! 🖨️ 🔥 Dr. @scottdehm led this study showing that androgen receptor (AR) alterations in ctDNA accumulate at progression in mCRPC patients treated with AR pathway inhibitors, especially in those with initially durable responses. bit.ly/49Iamij
1
9
289
It was a sheer pleasure to have @AdamSharpMedOnc here in Minnesota delivering a Cancer Center Seminar lecture about manipulation of the apoptosis pathway for prostate cancer therapeutics. Thanks @scottdehm for inviting and hosting him. Let the collaborations begin! @UMNCancer
2
2
1
24
4,916
Can anyone top the Halabi model for predicting survival in mCRPC? Yes! Dr Halabi does it again! See our ctDNA based clinical-genetic model in first line ARPI treatment out today in @EUplatinum: sciencedirect.com/science/ar… @scottdehm @DukeGUCancer @DukeCancer @PCFnews
4
15
584
Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm nature.com/articles/s43018-0…
1
2
8
314
Scott Dehm retweeted
Check out our new work exploring AR biology in advanced prostate cancer: tinyurl.com/2s39jh8b. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy
1
3
1
14
1,190
🧪 Dr. @scottdehm and collaborators including @huang_lab, @EAntonarakis, & @mishabeltran showed that double-negative #CRPC cells express genes defining basal, club, and hillock epithelial cells from benign #prostate. @PNASNews | bit.ly/4gI7fH3
2
8
543
Scott Dehm retweeted
Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant @marina_sharifi and @JSperger @AACR Funded by @PCF_Science @NIH @CDMRP
Now online in @CD_AACR: High-Purity Circulating Tumor Cell RNA Sequencing Identifies #ProstateCancer Lineage Phenotypes Prognostic for Clinical Outcomes - by @marina_sharifi, @JSperger, Shuang Zhao, @JoshLangMD et al. doi.org/10.1158/2159-8290.CD… @UWCarbone @UWMadison #LiquidBiopsy
7
15
2
68
7,156
In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science sciencedirect.com/science/ar…
5
53
3
199
17,299
The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm aacrjournals.org/clincancerr…
1
16
1
66
4,880
PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects various CRPC phenotypes. @CD_AACR . Lead our own @mishabeltran @DanaFarber_GU aacrjournals.org/cancerdisco…
1
8
21
3,050
It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical clinical need given that ctDNA-based biomarker genotyping can be limited by low ctDNA @NatureComms nature.com/articles/s41467-0…
7
77
4
187
31,237
PROSTATE Paper 3 Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC in @ALLIANCE_org A031201 ph3 trial of enzalutamide w/ or w/o abiraterone. The ctDNA assay was able to prognosticate outcomes, as pts w/ mCRPC who were ctDNA-pos vs. neg had significantly worse median OS (29.0 vs. 47.4 months, resp)! @NatureComms @scottdehm nature.com/articles/s41467-0…
2
11
18
3,178
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in Nature Communications nature.com/articles/s41467-0… This study introduces a custom circulating tumor DNA (ctDNA) 🧬sequencing assay, AR-ctDETECT, designed to detect ctDNA in the limited plasma cell-free DNA (cfDNA) of patients with metastatic castration-resistant hashtag#ProstateCancer (mCRPC). In the Alliance A031201 randomized phase 3 trial, involving 776 mCRPC patients treated with enzalutamide with or without abiraterone, 59% of patients were ctDNA-positive. Among these, 26% had high ctDNA aneuploidy, and 33% had low ctDNA aneuploidy but exhibited androgen receptor (AR) gain, structural rearrangements, MYC/MYCN gain, or pathogenic mutations. The study found that ctDNA-positive patients had significantly worse overall survival (29.0 months) compared to ctDNA-negative patients (47.4 months). This highlights ctDNA positivity as a strong prognostic marker for poor survival in mCRPC, even with AR inhibitor treatments. @charlesryanmd @EAntonarakis @AarmstrongDuke @scottdehm ping @nataliagandur @bavilima @Silke_Gillessen @AOmlin @ProfKHerrmann @stefanofanti4 #APCCCDiagnostics25
1
14
27
2,392
Susan Halabi representing @DukeGUCancer at #ASCO24 presenting our @ALLIANCE_org clinical genetic model using the @scottdehm AR-ctDETECT ctDNA assay. The new Halabi+ model! @DukeCancer
5
15
1,438
Susan Halabi ⁦@DukeCancer⁩ presents data on genetic perturbations and outcomes in the Alliance RCT of enz +/- abi and the findings are really interesting from a clinical biology standpoint! ⁦@ASCO⁩ #asco24 ⁦@PCF_Science⁩ Additional kudos to ⁦@scottdehm⁩!
2
4
1
20
2,057
The next-gen Halabi model. ctDNA content, AR enhancer gains, and other genomic factors add prognostic impact beyond clinical factors. Congrats to the Scott Dehm group for serving as the central ctDNA lab for this trial. @scottdehm
New Prognostic Model for mCRPC Susan Halabi @DukeCancer 🧬A new prognostic model incorporating clinical variables and ctDNA genetic alterations improving prediction of overall survival in mCRPC patients. @mishabeltran @EAntonarakis @DrRosenbergMSK @MattGalsky @charlesryanmd @morr316 @AarmstrongDuke @OncoAlert @PCFnews @APCCC_Lugano @ASCO #ASCO24
4
12
2,514
Susan Halabi and @AarmstrongDuke discuss new AR-ctDETECT assay and clinical-genetic prognostic model of OS in men w mCRPC, building on prior clinical models to develop new risk groups that teach us about biology & patient outcomes @DukeGUCancer @ALLIANCE_org @scottdehm
6
15
1,205
RT @DrChoueiri: #FengSymposium24 honoring our dear @felixfengmd organized by @DrPaulNguyen & @JoshLangMD with 250+ close friends. https://t…
1
4
Grateful for the 260 in-person attendees #FengSymposium & hundreds more around the world sending love and admiration for the greatest GU scientist, translator, clinical trialist, entrepreneur, mentor, and friend @felixfengmd & thank you @JoshLangMD for co-organizing!
5
33
7
186
24,752